Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay

[1]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[2]  R. Lutz,et al.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models , 2014, mAbs.

[3]  T. Chittenden,et al.  A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. , 2013, Blood.

[4]  R. Houot,et al.  A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma , 2013, Clinical Cancer Research.

[5]  A. Al-Katib,et al.  Targeting CD19 in B-cell lymphoma: emerging role of SAR3419 , 2013, Cancer management and research.

[6]  J. Lambert.  Drug‐conjugated antibodies for the treatment of cancer , 2013, British journal of clinical pharmacology.

[7]  P. LoRusso,et al.  Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. , 2012, Current drug metabolism.

[8]  H. Erickson,et al.  ADME of Antibody–Maytansinoid Conjugates , 2012, The AAPS Journal.

[9]  B. Gunter,et al.  The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.

[10]  R. Lutz,et al.  SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.

[11]  Rajeeva Singh,et al.  Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. , 2011, Bioconjugate chemistry.

[12]  E. Oroudjev,et al.  Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability , 2010, Molecular Cancer Therapeutics.

[13]  E. K. Maloney,et al.  Antibody-maytansinoid conjugates designed to bypass multidrug resistance. , 2010, Cancer Research.

[14]  G. Elia.  Biotinylation reagents for the study of cell surface proteins , 2008, Proteomics.

[15]  Yelena Kovtun,et al.  Semisynthetic maytansine analogues for the targeted treatment of cancer. , 2006, Journal of medicinal chemistry.

[16]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[17]  N. Damle,et al.  Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22. , 2004 .

[18]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[19]  H. Wiley,et al.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. , 2001, Molecular biology of the cell.

[20]  M. J. Mattes,et al.  Processing of antibodies bound to B‐cell lymphomas and lymphoblastoid cell lines , 1997, Cancer.

[21]  Y. Sugiyama,et al.  A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. , 1993, Bioconjugate chemistry.

[22]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[23]  Rajeeva Singh,et al.  Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. , 2010, Bioconjugate chemistry.